Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 251

1.

αB-crystallin Expression in Breast Cancer is Associated with Brain Metastasis.

Voduc KD, Nielsen TO, Perou CM, Harrell JC, Fan C, Kennecke H, Minn AJ, Cryns VL, Cheang MC.

NPJ Breast Cancer. 2015 Oct 21;1. pii: 15014.

2.

Attempt towards a novel classification of triple-negative breast cancer using immunohistochemical markers.

Liu YX, Wang KR, Xing H, Zhai XJ, Wang LP, Wang W.

Oncol Lett. 2016 Aug;12(2):1240-1256. Epub 2016 Jun 23.

3.
4.

Biology and Management of Patients With Triple-Negative Breast Cancer.

Sharma P.

Oncologist. 2016 Sep;21(9):1050-62. doi: 10.1634/theoncologist.2016-0067. Epub 2016 Jul 11. Review.

PMID:
27401886
5.

Cancer Hallmarks, Biomarkers and Breast Cancer Molecular Subtypes.

Dai X, Xiang L, Li T, Bai Z.

J Cancer. 2016 Jun 23;7(10):1281-94. doi: 10.7150/jca.13141. eCollection 2016. Review.

6.

Characterization of Cell-Type-Specific Drug Transport and Resistance of Breast Cancers Using Tumor-Microenvironment-on-Chip.

Shin K, Klosterhoff BS, Han B.

Mol Pharm. 2016 Jul 5;13(7):2214-23. doi: 10.1021/acs.molpharmaceut.6b00131. Epub 2016 Jun 10.

PMID:
27228477
7.

Clinicopathological Significance of Vimentin and Cytokeratin Protein in the Genesis of Squamous Cell Carcinoma of Cervix.

Husain NE, Babiker AY, Albutti AS, Alsahli MA, Aly SM, Rahmani AH.

Obstet Gynecol Int. 2016;2016:8790120. doi: 10.1155/2016/8790120. Epub 2016 Apr 14.

8.

Molecular subtypes of breast carcinoma in Saudi Arabia. A retrospective study.

Alnegheimish NA, Alshatwi RA, Alhefdhi RM, Arafah MM, AlRikabi AC, Husain S.

Saudi Med J. 2016 May;37(5):506-12. doi: 10.15537/smj.2016.5.15000.

9.

Identification of BRCA1 Deficiency Using Multi-Analyte Estimation of BRCA1 and Its Repressors in FFPE Tumor Samples from Patients with Triple Negative Breast Cancer.

Korlimarla A, Prabhu JS, Remacle J, Rajarajan S, Raja U, C E A, Srinath BS, Manjunath S, K S G, Correa M, M S N P, Sridhar TS.

PLoS One. 2016 Apr 14;11(4):e0153113. doi: 10.1371/journal.pone.0153113. eCollection 2016.

10.

Quantification of HER2 heterogeneity in breast cancer-implications for identification of sub-dominant clones for personalised treatment.

Buckley NE, Forde C, McArt DG, Boyle DP, Mullan PB, James JA, Maxwell P, McQuaid S, Salto-Tellez M.

Sci Rep. 2016 Mar 21;6:23383. doi: 10.1038/srep23383.

11.

Triple Negative Breast Cancer versus Non-Triple Negative Breast Cancer Treated with Breast Conservation Surgery Followed by Radiotherapy: A Systematic Review and Meta-Analysis.

Pan XB, Qu S, Jiang YM, Zhu XD.

Breast Care (Basel). 2015 Dec;10(6):413-6. doi: 10.1159/000441436. Epub 2015 Nov 24. Review.

PMID:
26989362
12.

Stratification of Prognosis of Triple-Negative Breast Cancer Patients Using Combinatorial Biomarkers.

Yue Y, Astvatsaturyan K, Cui X, Zhang X, Fraass B, Bose S.

PLoS One. 2016 Mar 1;11(3):e0149661. doi: 10.1371/journal.pone.0149661. eCollection 2016.

13.

Metformin attenuates transforming growth factor beta (TGF-β) mediated oncogenesis in mesenchymal stem-like/claudin-low triple negative breast cancer.

Wahdan-Alaswad R, Harrell JC, Fan Z, Edgerton SM, Liu B, Thor AD.

Cell Cycle. 2016;15(8):1046-59. doi: 10.1080/15384101.2016.1152432.

PMID:
26919310
14.

Characterization of MTAP Gene Expression in Breast Cancer Patients and Cell Lines.

de Oliveira SF, Ganzinelli M, Chilà R, Serino L, Maciel ME, Urban Cde A, de Lima RS, Cavalli IJ, Generali D, Broggini M, Damia G, Ribeiro EM.

PLoS One. 2016 Jan 11;11(1):e0145647. doi: 10.1371/journal.pone.0145647. eCollection 2016.

15.

Serum deprivation response inhibits breast cancer progression by blocking transforming growth factor-β signaling.

Tian Y, Yu Y, Hou LK, Chi JR, Mao JF, Xia L, Wang X, Wang P, Cao XC.

Cancer Sci. 2016 Mar;107(3):274-80. doi: 10.1111/cas.12879. Epub 2016 Feb 13.

16.

Heterogeneity of luminal breast cancer characterised by immunohistochemical expression of basal markers.

Sung H, Garcia-Closas M, Chang-Claude J, Blows FM, Ali HR, Figueroa J, Nevanlinna H, Fagerholm R, Heikkilä P, Blomqvist C, Giles GG, Milne RL, Southey MC, McLean C, Mannermaa A, Kosma VM, Kataja V, Sironen R, Couch FJ, Olson JE, Hallberg E, Olswold C, Cox A, Cross SS, Kraft P, Tamimi RM, Eliassen AH, Schmidt MK, Bolla MK, Wang Q, Easton D, Howat WJ, Coulson P, Pharoah PD, Sherman ME, Yang XR.

Br J Cancer. 2016 Feb 2;114(3):298-304. doi: 10.1038/bjc.2015.437. Epub 2015 Dec 17.

PMID:
26679376
17.

The fate of chemoresistance in triple negative breast cancer (TNBC).

O'Reilly EA, Gubbins L, Sharma S, Tully R, Guang MH, Weiner-Gorzel K, McCaffrey J, Harrison M, Furlong F, Kell M, McCann A.

BBA Clin. 2015 Mar 12;3:257-75. doi: 10.1016/j.bbacli.2015.03.003. eCollection 2015 Jun. Review.

18.

Cell surface GRP78: A potential marker of good prognosis and response to chemotherapy in breast cancer.

Yerushalmi R, Raiter A, Nalbandyan K, Hardy B.

Oncol Lett. 2015 Oct;10(4):2149-2155. Epub 2015 Aug 6.

19.

High incidence of triple negative breast cancers following pregnancy and an associated gene expression signature.

Asztalos S, Pham TN, Gann PH, Hayes MK, Deaton R, Wiley EL, Emmadi R, Kajdacsy-Balla A, Banerji N, McDonald W, Khan SA, Tonetti DA.

Springerplus. 2015 Nov 19;4:710. doi: 10.1186/s40064-015-1512-7. eCollection 2015.

20.

A Comparison of Clinical Features, Pathology and Outcomes in Various Subtypes of Breast Cancer in Indian Women.

Mane A, Khatib KI, Deshmukh SP, Nag SM, Sane SP, Zade BP.

J Clin Diagn Res. 2015 Sep;9(9):PC01-4. doi: 10.7860/JCDR/2015/15253.6461. Epub 2015 Sep 1.

Items per page

Supplemental Content

Write to the Help Desk